Abstract: A system, method and non-transitory computer readable storage medium for storing data for a plurality of entities, the data including values for a plurality of characteristics of each of the entities, receiving an identification of one of the entities as a target entity, calculating a distance from the target entity to each other entity not identified as the target entity, wherein the distance is calculated based on the values of the characteristics for the target entity and each of the other entities and identifying a predetermined number of the other entities as relevant entities, wherein the identifying is based on the distance calculated for each of the other entities.

Abstract: The invention provides live attenuated avirulent strains of Francisella tularensis, as well as methods for their preparation and use in protecting a mammal against infection with F. tularensis and against tularemia.

Abstract: The present invention relates to topors and its association with cancer. Topors antibodies are provided for use in diagnosing cancer based upon the absence of topors in a given cell or tissue sample. The detection of topors nucleic acid molecules in the diagnosis of cancer is also provided.

Abstract: Use of a compound of formula I wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R? is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, alone or in combination with at least one compound selected from the group consisting of somatostatin or a synthetic derivative thereof, interferon, 5-fluorouracil, doxorubicin, cyclophosphamide, streptozotocin and a standard anti-diarrheal, for the preparation of a medicament for the treatment of carcinoid syndrome or at least one neuroendocrine tumor; a method of treating a warm-blooded animal, having carcinoid syndrome and/or at least one neuroendocrine tumor; a combination comprising a compound formula I as defined above and at least one compound selected from the group provided above; and to a commercial package comprising said combination.

Abstract: Use of a compound of formula (I) wherein A represents or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R? is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, alone or in combination with at least one compound selected from the group consisting of somatostatin or a synthetic derivative thereof, interferon-5-fluorouracil, doxorubicin, cyclophosphamide, streptozotocin and a standard anti-diarrheal, for the preparation of a medicament for the treatment of carcinoid syndrome or at least one neuroendocrine tumor, a method of treating a warm-blooded animal, having carcinoid syndrome and/or at least one neuroendocrine tumor, a combination comprising a compound formula I as defined above and at least one compound selected from the group provided above; and to a commercial package comprising said combination.

Abstract: A method of selecting allocated communication channels for use by a cellular auxiliary personal communication system (CAPCS) comprising periodically collecting relative signal strength indication (RSSI) measurements for all allocated communication channels, periodically determining the estimated expected probability of non-interference for each allocated communication channel based on the relative signal strength indication measurements and selecting an available allocated communication channel having the highest estimated expected probability of non-interference for use by the CAPCS system. The relative signal strength indication measurements are made on the allocated communication channels by measuring the signal on the allocated communication channel when no call is being carried by the CAPCS on that channel.